当前位置: X-MOL 学术Int. J. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
High dose statin treatment reduces circulating Dickkopf-1 following acute myocardial infarction
International Journal of Cardiology ( IF 3.5 ) Pub Date : 2024-04-09 , DOI: 10.1016/j.ijcard.2024.132035
Thor Ueland , Noreen Butt , Tove Lekva , Stein Ørn , Cord Manhenke , Pål Aukrust , Alf Inge Larsen

Secreted glycoproteins of the Dickkopf (DKK) family modify Wnt signaling and may influence plaque destabilization but their modulation by statins in MI patients is not known. We measured plasma DKK-1 and DKK-3 in patients with acute ST-segment elevation MI (STEMI) before percutaneous coronary intervention (PCI) and after 2 and 7 days and 2 months in patients receiving short-term high-dose (40 mg rosuvastatin, given before PCI; = 25) and moderate dose (20 mg simvastatin, given the day after PCI; = 34). In vitro modulation of DKK-1 in human umbilical vein endothelial cells (HUVECs) by statins were assessed. (i) Patients receiving high dose rosuvastatin had a marked decline in DKK-1 at day 2 which was maintained throughout the study period. However, a more prevalent use of β-blockers in the simvastatin group, that could have contributed to higher DKK-1 levels in these patients. (ii) There was a strong correlation between baseline DKK-1 levels and change in DKK-1 from baseline to day 2 in patients receiving high dose rosuvastatin treatment. iii DKK-3 increased at day 2 but returned to baseline levels at 2 months in both treatment groups. (iv) Statin treatment dose-dependently decreased DKK-1 mRNA and protein levels in HUVEC. Our findings suggest that high dose statin treatment with 40 mg rosuvastatin could persistently down-regulate DKK-1 levels, even at 2 months after the initial event in STEMI patients

中文翻译:

高剂量他汀类药物治疗可减少急性心肌梗死后的循环 Dickkopf-1

Dickkopf (DKK) 家族的分泌糖蛋白会改变 Wnt 信号传导,并可能影响斑块不稳定,但他汀类药物对 MI 患者的调节作用尚不清楚。我们测量了急性 ST 段抬高型心肌梗死 (STEMI) 患者在经皮冠状动脉介入治疗 (PCI) 前以及接受短期高剂量(40 mg)治疗后 2、7 天和 2 个月后的血浆 DKK-1 和 DKK-3。瑞舒伐他汀,PCI 前给予;= 25)和中等剂量(20 mg 辛伐他汀,PCI 后一天给予;= 34)。评估了他汀类药物对人脐静脉内皮细胞 (HUVEC) 中 DKK-1 的体外调节作用。 (i) 接受高剂量瑞舒伐他汀的患者在第 2 天 DKK-1 显着下降,并且在整个研究期间一直保持这种下降。然而,辛伐他汀组更普遍使用 β 受体阻滞剂,这可能导致这些患者的 DKK-1 水平较高。 (ii) 在接受高剂量瑞舒伐他汀治疗的患者中,基线 DKK-1 水平与 DKK-1 从基线到第 2 天的变化之间存在很强的相关性。 iii 两个治疗组的 DKK-3 在第 2 天增加,但在 2 个月时恢复到基线水平。 (iv) 他汀类药物治疗剂量依赖性地降低 HUVEC 中的 DKK-1 mRNA 和蛋白质水平。我们的研究结果表明,用 40 mg 瑞舒伐他汀进行高剂量他汀治疗可以持续下调 DKK-1 水平,即使在 STEMI 患者初次事件后 2 个月也是如此
更新日期:2024-04-09
down
wechat
bug